Objective: To explore the curative effect of sequential triple therapy with ranitidine and omeprazole and its influences on serum C-reactive protein (CRP) and interleukin-6 (IL-6) in patients with Helicobacter pylori (Hp)-positive peptic ulcer. Methods: A total of 60 patients with Hp-positive peptic ulcer admitted to Nancheng County People"s Hospital were enrolled as the research objects between January 2023 and January 2024. According to random number table method, they were divided into control group (omeprazole triple therapy) and sequential group (omeprazole on the 1th week, ranitidine triple therapy on the 2nd week), 30 cases in each group. All patients were continuously treated for 3 weeks. The clinical curative effect, serum inflammatory factors, Hp clearance rate, recurrence rate and incidence of adverse reactions were compared between the two groups. Results: After 3 weeks of treatment, total response rates in sequential group and control group were 90.00% and 86.67%, and there was no significant difference in clinical curative effect between the two groups (P>0.05). After treatment, levels of serum interleukin-6, C-reactive protein and procalcitonin in sequential group were lower than those in control group (P<0.05). After 3 weeks of treatment, there was no significant difference in Hp clearance rate between sequential group and control group (96.67% vs 93.33%, P>0.05). The recurrence rate in sequential group was lower than that in control group (6.67% vs 30.00%, P<0.05). There was no significant difference in incidence of adverse reactions between sequential group and control group (20.00% vs 23.33%, P>0.05). Conclusion: Ranitidine combined with omeprazole can reduce levels of inflammatory factors and recurrence rate in patients with Hp-positive peptic ulcer.